Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept for Anemia in Beta-Thalassemia and MDS
NCT05891249Phase 4Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2023
- Primary completion
- Dec 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of luspatercept in anemia, sponsored by Bristol Myers Squibb. Started Jun 2023; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05891249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891249.